Linked Life Data

3254032

Source:http://linkedlifedata.com/resource/pubmed/id/3254032

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1989-8-14
pubmed:abstractText
A total of 23 previously untreated and 28 previously treated GH deficient children were included for at least 12 months in a trial of recombinant somatropin, 0.1 IU/kg/day given by subcutaneous injection. All the children increased their height velocity over the pretreatment values, to nearly 11 cm/year, corresponding to a significant increase in height of 1 SD score for chronological age. The increase in height SD score for bone age was also statistically significant. No adverse effects were recorded, though one child experienced local itching and redness at the injection site which did not recur after a short cessation of therapy. One child developed detectable antibodies to recombinant somatropin, but the binding capacity was low and no clinical symptoms or growth attenuation occurred. Recombinant somatropin was shown to be safe and effective during the first year of therapy in children with GH deficiency.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0300-8843
pubmed:author
pubmed:issnType
Print
pubmed:volume
347
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
176-9
pubmed:dateRevised
2008-2-20
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Recombinant somatropin in treatment of growth hormone deficient children in Sweden and Finland.
pubmed:affiliation
Department of Paediatrics II, University of Gothenburg, Sweden.
pubmed:publicationType
Journal Article